Brought to you by 
Boston Scientific, NitroMed develop NO stents-- concluded
29 Dec 2005
Executive Summary
Under a two-year research agreement, NitroMed (drugs enhanced by nitric oxide) licensed Boston Scientific exclusive, worldwide development and commercialization rights to two NO-releasing compounds. The companies plan to develop NO-coated stents to treat, reduce, or prevent restenosis, the re-narrowing of a previously treated artery.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Implantable Devices
Deal Status
- Concluded
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boston Scientific, NitroMed develop NO stents-- concluded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice